Most Favored Patient Act of 2026
Sponsored By: Representative Meuser
Introduced
Summary
Creates a Most Favored Nations drug-pricing test that ties certain U.S. drug prices to lower prices abroad. This bill would direct the Center for Medicare and Medicaid Innovation to run an MFN pricing model for specified Part B and Part D drugs and to add the model to program rules beginning in 2029.
Show full summary
- Manufacturers would have to offer the MFN price to MFN-eligible individuals and to pharmacies, mail-order dispensers, hospitals, clinicians, and other providers. They must also report pricing and sales data to the Secretary, and the Secretary can suspend MFN rules for a drug until April 1, 2029 if a covered agreement is likely.
- People enrolled in Medicaid, Medicare Part D, or receiving Part B drugs would be eligible to receive covered drugs at the MFN price when dispensed or administered. Pharmacies, hospitals, and clinicians are explicitly included as points of access.
- The MFN price is defined as the second-lowest applicable net price among eight reference countries and is adjusted for purchasing power. The test applies to drugs sold in two or more reference countries and would run for 5 years.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Most Favored Nation drug prices for Medicare, Medicaid
This bill would create a five-year Most Favored Nation (MFN) drug pricing test starting January 1, 2029. Manufacturers without a covered agreement would have to give MFN prices to eligible Medicare and Medicaid patients and to pharmacies and providers who dispense or administer the drugs. The MFN price would be the second-lowest average price paid in a group of reference countries, after rebates and discounts and adjusted for purchasing power. Manufacturers would also have to report pricing and sales data the Secretary needs to calculate MFN prices. The Secretary could pause MFN rules for a drug until April 1, 2029 if a manufacturer is likely to sign a covered agreement by December 31, 2028; covered agreements must include MFN access, reporting, and a commitment to increase U.S. manufacturing.
Sponsors & CoSponsors
Sponsor
Meuser
PA • R
Cosponsors
There are no cosponsors for this bill.
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in